Sandbox Lopressor

Sandbox Lopressor®
Black Box Warning
Adult Indications and Dosage   FDA-Labeled Use   Off-Label Use
Pediatric Indications and Dosage   FDA-Labeled Use   Off-Label Use
Contraindications
Warnings
Adverse Reactions   Clinical Trials Experience   Postmarketing Experience
Drug Interactions
Use in Specific Populations   Pregnancy   Labor and Delivery   Nursing Mothers   Pediatric Use   Geriatric Use   Gender   Race   Renal Impairment   Hepatic Impairment   Females of Reproductive     Potential and Males   Immunocompromised Patients
Routes and Preparations   Routes   Preparations
IV Compatibility
Overdosage
Pharmacology   Mechanism of Action   Structure   Pharmacodynamics   Pharmacokinetics   Nonclinical Toxicology
Clinical Studies
How Supplied
Images   Drug Images   Package & Label Display Panel
Patient Information   Patient Information from FDA   Patient Information from NLM
Combined Alcohol Use
Look-Alike Drug Names
Drug Shortage Status
Price

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Disclaimer

WikiDoc Drug Project is a constellation of drug information for healthcare providers and patients vigorously vetted on the basis of FDA package insert, MedlinePlus, Practice Guidelines, Scientific Statements, and scholarly medical literature. The information provided is not a medical advice or treatment. WikiDoc does not promote any medication or off-label use of drugs.

Black Box Warning

WARNING See full prescribing information for complete boxed warning. Ischemic Heart Disease: Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. When discontinuing chronically administered Lopressor, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of 1-2 weeks and the patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, Lopressor administration should be reinstated promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician’s advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue Lopressor therapy abruptly even in patients treated only for hypertension.

Dosage and Administration

Dosage Forms and Strengths

Indications and Usage

Contraindications

Warnings and Precautions

Adverse Reactions

Drug Interactions

Use in Specific Populations

Overdosage

Description

Mechanism of Action

Clinical Pharmacology

Nonclinical Toxicology

Clinical Studies

How Supplied/Storage and Handling

Patient Counseling Information

Labels and Packages

Pill Images and Characteristics

Pricing

Black box warning Dosing information Mechanism of action Indications Contraindications Warnings and Precautions Adverse reactions Drug Interactions Overdosage Pharmacology Clinical studies Patient counseling information Pill images and characteristics

Dosing Information

Dosage and Administration

Dosage Forms and Strengths

How Supplied/Storage and Handling

Pharmacology

Description

Clinical Pharmacology

Nonclinical Toxicology

Use in Specific Populations